Loading…
Central Admixture Pharmacy Services, Inc., an outsourcing facility registered to compound sterile drug products, received a warning for serious deficiencies in its sterile drug manufacturing practices discovered during an FDA inspection from June to July 2023. The facility produced drugs that violated the Federal Food, Drug, and Cosmetic Act by failing to ensure sterility assurance in compounded products, prompting the company to cease production on August 4, 2023, and initiate voluntary recalls of sterile drug products on July 14 and August 17, 2023. These compliance failures posed a significant risk to patients relying on these compounded sterile medications.